UPDATE: Recordati posts strong sales and earnings growth for 1st-qtr

10 May 2022

Italian drugmaker Recordati (REC: MI) saw its shares gain 2.1% to 42.31 euros by early afternoon, as the company released first-quarter 2022 financial results.

Consolidated net revenue in the first quarter was 419.4 million euros ($443.7 million), compared to 384.8 million euros in the first quarter of last year (+9.0% or +10.9% at constant exchange rates), reflecting the recovery in relevant markets (especially with regard to Cough & Cold and OTC products), the robust performance of rare disease business, and the greater contribution from Eligard (leuprorelin acetate), licensed in January 2021.

Net income at 96.7 million euros, was up 7.6%, accounting for 23.1% of revenue. The increase is due to higher operating income and the lower incidence of financial charges due to lower FX losses. Adjusted net income was 116.3 million euros, up by 11.4% over the same period in 2021, at 27.7% of revenue.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK